Multivariate analysis using the Cox proportional hazards model demonstrated that high levels of baseline plasma IL-6 were predictors of shorter PFS in HCC patients who underwent Atezo/Bev therapy, independent of disease stage and liver function. This evidence concerns the gene IL6 and hepatocellular carcinoma.